Hôpital du Sacré-Cœur de Montréal

Running trials

• Not yet recruiting

  Effects of Smartphone Use and Television Viewing on Standardized BP Measurement: The SCREENS-BP Study

  NCT07903779· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Not yet recruiting

  Dialysis Less Frequently in the Elderly

  NCT07738731· Queen's University· Source

• Not yet recruiting

  Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury III (PROMPT-SCI III) Trial

  NCT07798310· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Recruiting

  Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial

  NCT07472985· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Recruiting

  Shorter and Safer Treatment Regimens for Latent TB

  NCT06498414· Phase 2/3· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

  NCT06782373· Phase 2· Swedish Orphan Biovitrum· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Prevail Global Study

  NCT06535854· Medtronic Vascular· Source

• Not yet recruiting

  Early Pharmacological Treatment of Acute Spasticity After Spinal Cord Injury

  NCT06564714· Phase 4· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Recruiting

  Pericardiotomy in Cardiac Surgery

  NCT06486636· Population Health Research Institute· Source

• Active, not recruiting

  Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

  NCT06149650· Cardiovascular and Interventional Radiological Society of Europe· Source

• Active, not recruiting

  A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

  NCT06294925· Pfizer· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Active, not recruiting

  Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

  NCT06408935· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  Use of Point-of-care Neuro-sacral Electrophysiology Following Spinal Cord Injury

  NCT06333886· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Recruiting

  PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

  NCT05928039· Phase 4· University of Calgary· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Active, not recruiting

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

  NCT05406401· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

• Recruiting

  A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· Phase 3· AbbVie· Source

• Active, not recruiting

  Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

  NCT04988386· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Enrolling by invitation

  Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

  NCT04451044· Philips Clinical & Medical Affairs Global· Source

• Recruiting

  Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  NCT04774159· Phase 3· Population Health Research Institute· Source

• Recruiting

  Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

  NCT05100420· Montreal Heart Institute· Source

• Active, not recruiting

  Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

  NCT04401748· Phase 3· AbbVie· Source

• Active, not recruiting

  Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

  NCT04068103· Phase 2/3· NRG Oncology· Source

• Active, not recruiting

  SyncAV Post-Market Trial

  NCT04100148· Abbott Medical Devices· Source

• Active, not recruiting

  Long Term Follow Up for CTSN Mitral Valve Repair Studies

  NCT03066050· Icahn School of Medicine at Mount Sinai· Source

• Active, not recruiting

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease4 recruiting
• Spinal cord injury3 recruiting
• Chronic kidney disease2 recruiting
• Lung cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Peripheral artery disease2 recruiting
• Atrial fibrillation1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Stroke1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  Accuracy Testing of Validated and Non-validated Home BP Devices Sold on the Online Market.

  NCT06688409· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Completed

  A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

  NCT06001177· Phase 2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source

• Completed

  Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

  NCT06348173· Université de Montréal· Source

• Completed

  CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease

  NCT05163158· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Completed

  Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

  NCT05220501· Sunnybrook Health Sciences Centre· Source

• Completed

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator

  NCT05716334· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Terminated

  Concordance Between Central Blood PRessure dEvices In Nephrology Patients

  NCT05963880· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Completed

  Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury

  NCT04699474· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Completed

  Effectiveness of Anti-IL-5/IL5R Inhibitors

  NCT06239441· Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal· Source

• Completed

  Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

  NCT04295538· Phase 2· AbbVie· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Takeda· Source

• Recruiting

  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

  NCT04045665· Phase 3· Icahn School of Medicine at Mount Sinai· Source

• Completed

  Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

  NCT03946072· University of California, San Francisco· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source

• Completed

  A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  NCT03069352· Phase 3· AbbVie· Source

• Completed

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

  NCT02168829· Phase 4· Ottawa Heart Institute Research Corporation· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Population Health Research Institute· Source

• Terminated

  Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

  NCT02387229· Phase 3· Montreal Heart Institute· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lewy body dementia9 works · 0 trials